A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2025

Conditions

Advanced Solid Tumors

Interventions

DRUG

HRXG-K-1939

DRUG

Adebrelimab

Adebrelimab is a programmed death-ligand 1 antibody

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT05942378 - A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter